Format

Send to

Choose Destination
Invest New Drugs. 2015 Dec;33(6):1292. doi: 10.1007/s10637-015-0287-6.

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Author information

1
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
2
GlaxoSmithKline, Collegeville, PA, USA.
3
Medimmune, Gaithersburg, MD, USA. adamsla@medimmune.com.
4
Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, Durham, NC, USA. adamsla@medimmune.com.
5
Janssen Research & Development, Spring House, PA, USA.
6
Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, Durham, NC, USA.
7
CSL Behring, King of Prussia, PA, USA.
8
Astex Pharmaceuticals, Inc., Pleasanton, CA, USA.
9
Exelixis, South San Francisco, CA, USA.
10
Genentech, San Francisco, CA, USA.
11
Biomarker, Translational & Predictive Medicine Consulting, San Francisco, CA, USA.
12
University of Chicago, Chicago, IL, USA.
13
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Collegeville, PA, USA.
14
NantOmics, LLC, Rockville, MD, USA.
15
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
16
Yale Cancer Center, New Haven, CT, USA.
17
Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.
PMID:
26407571
DOI:
10.1007/s10637-015-0287-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center